Letting bias in through the back door? Trial Statisticians: the not-so-independent members of an Independent Data Monitoring Committee

Louise Marston¹ Senior Research Statistician
David R McKenzie² Senior Director
Nick Freemantle¹ Professor of clinical epidemiology & biostatistics

Affiliations
¹Department of Primary Care and Population Health and Priment Clinical Trials Unit, UCL, London, UK
²Biometrics, Covance, 206 Carnegie Center, Princeton, NJ 08540-6233

Please address correspondence to:
Dr Louise Marston PhD
Department of Primary Care and Population Health
University College London
Rowland Hill Street
London
NW3 2PF

Telephone 020 7794 0500 (31019)
Email l.marston@ucl.ac.uk

Word count: 850
Independent Data Monitoring Committees (DMCs, DSMBs, DMECs) aim to protect the interests of trial participants. The duty of care towards participants is paramount and should be untrammeled by conflicting interests.

Good Clinical Practice (GCP) provides direction on composition and operation of DMCs[1, 2]. ICH E9 states: “All staff involved in the conduct of the trial should remain blind to the results of… [interim] analyses, because of the possibility that their attitudes to the trial will be modified and cause changes in the characteristics of patients to be recruited or biases in treatment comparisons.” The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provided similar regulatory guidance.[3, 4] Neither requires the statistician performing the interim analyses to be independent or different from those involved in trial management and performing the final analyses. However the FDA[3] states: “the integrity of the trial may be best protected when the statisticians preparing unblinded data for the DMC are external to the sponsor and uninvolved in discussions regarding potential changes in trial design while the trial is ongoing.” Industry routinely implements this FDA guidance, but this is rarely the case in publically funded trials.

The risk of conflicts of interest in industry with the development of drugs is somewhat obvious, but conflicts may be less clear in academia. Academics do however have an interest in the success of their trials, which may lead to career advancement. Trial statisticians in UK and US government funded trials are often responsible for creating unblinded DMC reports and attending closed sections of meetings, undermining the principle of the committee being independent, with interim results from ongoing trials known by at least one of the management team. Many statisticians working on academic trials do not perceive this to be bias and some are reluctant to rescind their informed status. This is in breach of GCP.

Whether the allocations are explicit or data are analysed blind (e.g. described as groups ‘A’ and ‘B’), the statistician knows the potential treatments. It is our experience that they or DMC members will normally deduce the randomised allocation through the adverse event or outcome profiles.[5] In a recent trial, blood concentrations were higher in one randomised group, resulting in adverse events. The DMC clinicians identified the treatment groups, unblinding the trial statistician.

When trial statisticians present interim results to the DMC, they cannot avoid contributing to the interpretation. They are party to discussions between the independent DMC members and will exert influence despite being conflicted in discussions. Further, when the trial
management group to which they belong considers changing some aspect of the trial, for example inclusion criteria or the definition of the primary outcome, the trial statistician cannot put aside their knowledge. The statistician may know from the emerging data the implications for the trial.[6] This occurred in a trial of two vasectomy techniques.[7] Although the interim analyses were presented blinded, the DMC guessed the allocations, with the trial statistician party to this information. The trial statistician noticed an interaction. This was instrumental in stopping the trial despite the DMC recommending continuation.

One of us was a member of a DMC where the trial statistician presented the interim results; however the timing of the primary outcome was not defined in the protocol or statistical analysis plan. The primary analysis would thus be specified with knowledge of unfolding results, a clear source of bias. The trial statistician did not address the ambiguity which was also not addressed by the Trial Management Group; the DMC member subsequently resigned.

In 2005, the DAMOCLES group published a charter for DMCs.[8] They did not give guidance on who should undertake interim analyses or present them to the DMC, merely documented what usually happened.[9] Three alternative models were presented, including one where the statistician analysing data for the DMC would be semi-independent and a little removed from trial management. This charter has been widely adopted in UK publicly funded trials despite its recommendations being out with GCP. This may be because authors were employed by UK academic or research councils, which are not funded as generously as industry. A completely independent statistician would increase costs. However many clinical trials units include two statisticians in their grant applications. This would allow a compromise to involve (at least) two statisticians in all trials; one attending trial management meetings and performing the final analysis and the other performing the interim analyses, attending the DMC meetings as a non-voting member and confirming the final analysis. The second statistician would forfeit any trial management responsibilities from the point of first interim analysis.[3, 10, 11] A third independent, qualified and experienced statistician from a different centre would sit on the DMC as a voting member.

Society has a duty of care towards those who participate in research. Researchers have a responsibility to ensure they provide unbiased guidance to inform future care. DMCs should be independent and use their position only to intervene with trial management when there are serious safety concerns, or where efficacy can be established unequivocally. Properly constituted, independent DMCs should be established in all but the lowest risk trials.
References
1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6(R1) guideline for good clinical practice. 1996.


3. Food and Drug Administration Guidance for Clinical Trial Sponsors Establishment and Operation of Clinical Trial Data Monitoring Committees 2006

4. European Medicines Agency Guideline on Data Monitoring Committees 2005


LM, NF and DRM developed the idea for the article through their work and interaction. LM searched for information related to the conduct of DMC and wrote the first draft. NF and DRM contributed to the writing and editing of the paper.

Guarantor: Louise Marston

Funding

None

Conflict of interest

We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: NF has advised Sanofi Aventis, Ipsen, Novo Nordisk and academia on the design and analysis of randomised trials. He currently sits on Safety Committees for Daiichi Sankyo, Advanced Accelerator Applications, and contributes to a UK academic Clinical Trials Unit. LM contributes to a UK academic Clinical Trials Unit. DRM has no conflicts of interest.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd ("BMJ"), and its Licensees to permit this article (if accepted) to be published in The BMJ's editions and any other BMJ products and to exploit all subsidiary rights, as set out in our licence.